Crinetics Pharmaceuticals, Inc.
CRNX
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as weā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$35.61
Price+3.97%
$1.36
1Y
Price
Market Cap
$3.354b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-11514.8%
EBITDA Margin-10457.8%
Net Profit Margin-8466.9%
Free Cash Flow MarginRevenue
$1.392m
-50.8%
1y CAGR+91.1%
3y CAGR+422.9%
5y CAGREarnings
-$369.834m
-9.8%
1y CAGR-31.2%
3y CAGR-35.1%
5y CAGREPS
-$4.11
-2.4%
1y CAGR-11.0%
3y CAGR-12.3%
5y CAGRBook Value
$1.172b
$1.290b
Assets$118.048m
Liabilities$49.936m
DebtDebt to Assets
3.9%
-0.2x
Debt to EBITDAFree Cash Flow
-$307.798m
-7.9%
1y CAGR-28.5%
3y CAGR-32.1%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company